Clinical trials: Left Main Coronary Artery
Coronary Bifurcation Lesion, Coronary Artery Disease (CAD)
Crossover vs Accurate Ostial PCI for Medina 0.0.1 and 0.1.0 Left Main Bifurcation Lesions
Coronary artery disease is a leading cause of mortality and morbidity globally. The left coronary artery system is critically important due to its supply of a large area of myocardium.
- Conditions
- Coronary Bifurcation Lesion, Coronary Artery Disease (CAD), Left Main Coronary Artery Stenosis
- Trial name
- NCT07596706
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Istanbul Mehmet Akif Ersoy Educational and Training Hospital
Unprotected Left Main Coronary Artery Disease
Comparison of HYBRID Versus Two-Stent Strategies in Unprotected True Left MAIN Bifurcation
The number of deaths from heart disease is rising globally, particularly in developing countries. This condition involves the narrowing of arteries that supply blood to the heart.
- Trial name
- HYBRID MAIN (NCT07159737)
- Testing
- Two-stent strategy, Hybrid Strategy
- Volunteers
- 800 people
- Sponsor
- Hospital Sultanah Bahiyah
Acute Myocardial Infarction
Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
To compare short-term clinical outcomes of primary PCI between the ostial LAD-AMI and the non-ostial LAD-AMI. The primary endpoint was the major cardiovascular events (MACE) defined as being the composite of cardiac death, AMI…
- Trial name
- NCT04104048
- Volunteers
- 300 people
- Sponsor
- Assiut University
Coronary Artery Disease
The Rolex Registry (Revascularization Of LEft Main With Resolute onyX)
The primary objective of this study is to assess the safety and efficacy of the new-generation zotarolimus-eluting stent Resolute Onyx in the treatment of unprotected left main coronary artery disease (ULMCAD), both isolated or…
- Trial name
- Rolex (NCT03316833)
- Testing
- Resolute Onyx
- Where
- 33 sites in Italy, Portugal
- Volunteers
- 450 people
- Sponsor
- University of Padova
Coronary Disease
Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)
The purpose of this study is to evaluate the efficacy of sirolimus- and paclitaxel-eluting stents for treatment of unprotected left main coronary artery disease.
- Trial name
- NCT00133237
- Testing
- Sirolimus-eluting stent, Paclitaxel-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 607 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Study Examining the PROMUS Element Everolimus-eluting Stent in Multi-center Coronary Intervention of Complex Arterial Lesion Subsets
Randomized trials have demonstrated an excellent safety and efficacy profile for the chromium everolimus-eluting stent. The platinum chromium everolimus-eluting sten (PtCr-EES) uses the identical antiproliferative agent and…
- Trial name
- SPECIALIST (NCT01670318)
- Testing
- platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)
- Where
- 38 sites in Japan
- Volunteers
- 800 people
- Sponsor
- The PCI Guideline Research Society